Navigation Links
MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Date:8/19/2007

diabetes mellitus within

4-12 months of diagnosis

Pancreatic Led by Dr. Bernhard http://www.clinicaltrials.gov

islet cell Hering of the University (search for NCT00265473)

transplantation of Minnesota, this Phase

with teplizumab 2 trial funded by NIDDK

induction is enrolling patients

therapy less than 40 years old

who have been insulin

dependent for more

than 5 years

About Teplizumab

Teplizumab, also called MGA031 and hOKT3-gamma-1 (Ala-Ala), is a humanized monoclonal antibody engineered to alter the function of the T lymphocytes that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab binds to an epitope of the CD3-epsilon chain expressed on mature T cells and by doing so, may modulate the immunologic response that causes disease.

About Type 1 Diabetes

Type 1 diabetes is an autoimmune disease in which the body's immune system attacks and destroys the insulin-producing beta cells of the pancreas. The symptoms associated with type 1 diabetes can appear suddenly and leave a person dependent on injected insulin for life. The disease carries the constant threat of devastating complications such as heart and kidney disease, nerve damage and blindness. Although diagnosis most often occurs in childhood and adolescence, the disease can strike adults as well. Individuals with type 1 diabetes must test their blood sugar four or more times per day and take multiple insulin injections daily or continually infuse insulin through a pump. While trying to balance insulin doses with their food intake and daily activities, people with this form of diabetes must always be prepared for serious hypoglycemic (low blood sugar) and hyperglycemic (high blood sugar) reactions, both
'/>"/>

SOURCE MacroGenics, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
4. Global Rabies Treatment May be Possible with NanoViricides Drugs
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ariz. , July 10, 2014   Ventana ...  Group, today announced it has entered into an agreement ... which operates as EMD Serono in the ... , to collaborate with Merck KGaA,s biopharmaceutical division on ... for an undisclosed target using Ventana,s proprietary diagnostic assays. ...
(Date:7/10/2014)... BURLINGTON, Mass. , July 10, 2014 ... nephrologists report awareness of the U.S. Food and Drug ... Pharma,s new phosphate binder Velphoro, which was approved by ... hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... NEW YORK, Sept. 28, 2011 Visionsense Corp announces ... was used in its 500th neurosurgical procedure with the ... (Al Lerner Chair and Vice-Chairman, Dept of Neurosurgery at ... performed a transsphenoidal resection of a pituitary adenoma in ...
... Sept. 28, 2011 As part of its ongoing work ... settings, Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its ... event and global MRSA summit will be held on October ... Maywood, Ill. Organized by the MRSA Survivors ...
Cached Medicine Technology:Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day on October 1 2
(Date:7/11/2014)... MA (PRWEB) July 11, 2014 ... at least $50 billion in fuel costs ... immediately. The current GHG standards ... have taken it upon themselves to install ... include: , 1.    Idle reduction technologies , 2.    Efficient ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Ticket Down ... the Concord Pavilion . When it comes to the summer ... Bryan. The 37-year-old Georgia native is one of the biggest names ... entertainment business. Bryan is currently out on his “That’s My Kind ... many stops the tour will be making through the rest of ...
(Date:7/11/2014)... Global enterprises today are shifting towards ... management activities. Managed services offer these global enterprises a ... slowdown resulted into rising operational costs to companies. The ... to be the global market driver for expanding the ... managed services market is estimated to grow from $142.75 ...
(Date:7/11/2014)... The Miriam Hospital have found that people with ... rates of smoking than those without mobility impairments. ... to attempt quitting than those without mobility impairments, ... for this population. The study and its findings ... the American Journal of Public Health . ...
(Date:7/11/2014)... (HealthDay News) -- Delaying surgery to repair damage to the ... middle of the knee -- could increase a young athlete,s ... medical records of 130 patients, aged 8 to 16, who ... less than six weeks after their injury, 37 had surgery ... more than three months after their injury. The youngsters ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2
... even flying in business class can put people at ... flights.// ,The link between blood clots (venous ... War II, when doctors noticed a rise in fatal ... in London air raid shelters. The association was further ...
... simple new test to detect kidney cancer in its ... report published in this week’s Cancer Research, researchers outline ... urine., ,Kidney cancer accounts for about 3 percent ... the United States in 2003. Doctors currently use several ...
... Programs run by nurses and dieticians have been found ... analysis has shown they work only when these health ... ,Researchers looked at a program in which patients received ... by nurses and dieticians on factors aimed at improving ...
... A new study reveals that a tonsillectomy procedure using ... key to reducing pain during recovery. // ... scalpel heats tissue as it goes along to control ... less energy to achieve the same result, which means ...
... New research shows the drug efalizumab may reduce symptoms ... ,Researchers from Loyola University studied more than 550 ... efalizumab (Raptiva) or a placebo for three months. Researchers ... the degree of scaling and thickness. Patients also completed ...
... publishing in the most recent issue of The Lancet ... for the deadly Ebola virus.// ,In a ... a factor known to inhibit blood coagulation called rNAPc2 ... kills its victims by causing severe hemorrhagic fever. This ...
Cached Medicine News:
... grafting or creation of a vascular access, ... is of the utmost importance in many ... for those seeking a high-precision tunneling instrument. ... risk of twisting or kinking for more ...
... have met the challenges of the ... exceptional performance and quality, they have ... worldwide. These grafts require no preclotting, ... infection, and ensure utmost thrombectomy safety. ...
... the challenges of the most demanding vascular ... exceptional performance and quality, they have earned ... grafts require no preclotting, resist dilatation and ... thrombectomy safety. Gore vascular grafts are also ...
... the newest vascular graft offering from W. ... vascular surgical products for more than two ... and compression problems that can lead ... all of the benefits of a ring ...
Medicine Products: